We have read with great interest the article "New therapeutic agents in diabetic nephropathy" Korean J Intern Med 2017;32:11-25 by Yaeni Kim and Cheol Whee Park [1] . The authors stated that 'the Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY) trial using mineralocorticoid receptor blockers has shown limited efficacy in the early stages of diabetic nephropathy and concerns regarding the development of hyperkalemia need to be addressed.
We have read with great interest the article "New therapeutic agents in diabetic nephropathy" Korean J Intern Med 2017;32:11-25 by Yaeni Kim and Cheol Whee Park [1] . The authors stated that 'the Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY) trial using mineralocorticoid receptor blockers (MT-3995, BAY 94-3995, and BAY 94-8862) has shown limited efficacy in the early stages of diabetic nephropathy and concerns regarding the development of hyperkalemia need to be addressed.
This statement is not correct because: (1) the PRIORITY study is still ongoing, the results have not been reported yet [2] ; (2) secondly the drug being tested is this research is spironolactone and not MT-3995, BAY 94-3995, and BAY 94-8862; and (3) BAY 94-3995 does not exist.
If the authors would rather refer to BAY 94-8862 then we would like to underline the following: BAY 94-8862 has now an INN (international nonproprietary name) which is finerenone. Finerenone has shown in a phase IIb study in patients with diabetic kidney disease (DKD) a significant and dose-dependent reduction of urine albumin-to-creatinine ratio after 90 days. Hyperkalemia leading to discontinuation was not observed in the placebo and finerenone 10 mg groups; the incidence was 3.2% in the 15 mg group and ≤ 2.2% in all other finerenone groups. Therefore, the risk of hyperkalaemia was low in patients with DKD who received finerenone for 90 days in addition to standard of care [3] .
We hope that the authors will correct their publication accordingly.
